<DOC>
	<DOCNO>NCT00265382</DOCNO>
	<brief_summary>The purpose study assess safety tolerability ziprasidone long-term open-label administration adolescent ( age 13-17 ) schizophrenia .</brief_summary>
	<brief_title>Safety And Tolerability Of Ziprasidone In Adolescents With Schizophrenia</brief_title>
	<detailed_description>On March 24 , 2009 , Pfizer Inc. stop late stage Geodon pediatric clinical trial schizophrenia ( A1281134 - placebo control ; A1281135 - open label ) . As recommended DSMB , study stop due lack efficacy . No safety concern identify .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Ziprasidone</mesh_term>
	<criteria>Participation doubleblind treatment study A1281134 , meet specific criterion duration safety Imminent risk suicide homicide , judge site investigator Serious adverse event relate study medication study A1281134 Significant prolongation QT interval study A1281134</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>December 2011</verification_date>
	<keyword>Adolescent Subjects</keyword>
</DOC>